{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:32Z","timestamp":1794047492271,"version":"4.8.0"},"reference-count":17,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2024.286025","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T11:03:05Z","timestamp":1732186985000},"page":"980-984","source":"Crossref","is-referenced-by-count":2,"title":["FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome\/ chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des My\u00e9lodysplasies"],"prefix":"10.3324","volume":"110","author":[{"given":"Pierre","family":"Peterlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Gaschet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Turlure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Gourin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Thepot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Berceanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Hospital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cluzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose-Miguel","family":"Torregrosa-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Drevon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Sapena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatiha","family":"Chermat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Ades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Dimicoli-Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Jullien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Chevallier.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"74390","doi-asserted-by":"crossref","unstructured":"Chan O, Renneville A, Padron E. Chronic myelomonocytic leukemia diagnosis and management. Leukemia. 2021; 35(6):1552-1562.","DOI":"10.1038\/s41375-021-01207-3"},{"key":"74391","doi-asserted-by":"crossref","unstructured":"Sekeres MA, Taylor J. Diagnosis and treatment of myelodysplastic syndromes: a review. JAMA. 2022; 328(9):872-880.","DOI":"10.1001\/jama.2022.14578"},{"key":"74392","doi-asserted-by":"crossref","unstructured":"Peterlin P, Le Bris Y, Turlure P. CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Haematol. 2023; 10(7):e521-e529.","DOI":"10.1016\/S2352-3026(23)00090-X"},{"key":"74393","doi-asserted-by":"crossref","unstructured":"Peterlin P, Gaschet J, Guillaume T. A new cytokine-based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia. Cancer Med. 2021; 10(2):642-648.","DOI":"10.1002\/cam4.3648"},{"key":"74394","doi-asserted-by":"crossref","unstructured":"Peterlin P, Gaschet J, Bertoli S. Fms-like tyrosine kinase 3 Ligand kinetic profile is the strongest factor predicting refractoriness after induction and event-free survival in adults with AML: a Filo prospective multicentric study. Blood. 2023; 142(Suppl 1):975.","DOI":"10.1182\/blood-2023-173518"},{"key":"74395","doi-asserted-by":"crossref","unstructured":"Tsapogas P, Mooney CJ, Brown G, Rolink A. The cytokine Flt3-ligand in normal and malignant hematopoiesis. Int J Mol Sci. 2017; 18(6):1115.","DOI":"10.3390\/ijms18061115"},{"key":"74396","doi-asserted-by":"crossref","unstructured":"Zwierzina H, Anderson JE, Rollinger-Holzinger I, Torok-Storb B, Nuessler V, Lyman SD. Endogenous FLT-3 ligand serum levels are associated with disease stage in patients with myelodysplastic syndromes. Leukemia. 1999; 13(4):553-557.","DOI":"10.1038\/sj.leu.2401378"},{"key":"74397","doi-asserted-by":"crossref","unstructured":"Lynch OF, Calvi LM. Immune dysfunction, cytokine disruption, and stromal changes in myelodysplastic syndrome: a review. Cells. 2022; 11(3):580.","DOI":"10.3390\/cells11030580"},{"key":"74398","doi-asserted-by":"crossref","unstructured":"Franzini A, Pomicter AD, Yan D. The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations. Blood Adv. 2019; 3(20):2949-2961.","DOI":"10.1182\/bloodadvances.2019000585"},{"key":"74399","doi-asserted-by":"crossref","unstructured":"Winter S, Shoaie S, Kordasti S, Platzbecker U. Integrating the \u201cImmunome\u201d in the stratification of myelodysplastic syndromes and future clinical trial design. J Clin Oncol. 2020; 38(15):1723-1735.","DOI":"10.1200\/JCO.19.01823"},{"key":"74400","doi-asserted-by":"crossref","unstructured":"Pardanani A, Finke C, Lasho TL. IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. Leukemia. 2012; 26(4):693-699.","DOI":"10.1038\/leu.2011.251"},{"key":"74401","doi-asserted-by":"crossref","unstructured":"Liu Z, Xu X, Zheng L. The value of serum IL-4 to predict the survival of MDS patients. Eur J Med Res. 2023; 28(1):7.","DOI":"10.1186\/s40001-022-00948-w"},{"key":"74402","doi-asserted-by":"crossref","unstructured":"Shi C, Gong S, Niu T. The prognostic value of pretherapy peripheral blood inflammatory indices in myelodysplastic syndromes. Front Oncol. 2022; 12:877981.","DOI":"10.3389\/fonc.2022.877981"},{"key":"74403","doi-asserted-by":"crossref","unstructured":"Niyongere S, Lucas N, Zhou JM. Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. Leukemia. 2019; 33(1):205-216.","DOI":"10.1038\/s41375-018-0203-0"},{"key":"74404","doi-asserted-by":"crossref","unstructured":"Stahl M, Bewersdorf JP, Giri S, Wang R, Zeidan AM. Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. Haematologica. 2020; 105(1):102-111.","DOI":"10.3324\/haematol.2019.219345"},{"key":"74405","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Estey E, Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4):424-447.","DOI":"10.1182\/blood-2016-08-733196"},{"key":"74406","doi-asserted-by":"crossref","unstructured":"Zeidan AM, Platzbecker U, Bewersdorf JP. Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes. Blood. 2023; 141(17):2047-2061.","DOI":"10.1182\/blood.2022018604"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11836\/77800","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11836\/78246","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11836\/77800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:41Z","timestamp":1794046061000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":17,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286025","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}